Search results for "EOSINOPHILIA"

showing 5 items of 75 documents

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review.

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue.This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-relat…

medicine.medical_specialtymedicine.medical_treatmentmacromolecular substances030226 pharmacology & pharmacyDrug reaction with eosinophilia and systemic symptoms03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsAntipsychoticClozapineClozapinebusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseDermatologyHypersensitivity reactionnervous system030220 oncology & carcinogenesisDrug Hypersensitivity SyndromePolypharmacySchizophreniabusinessmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Single and Synergistic Effects of Type 2 Cytokines on Eosinophils and Asthma Hallmarks

2020

Abstract The type 2 cytokines IL-5, IL-13, and IL-4 play an important role in the induction and progression of asthma. According to the Global Initiative for Asthma guidelines, blood eosinophil numbers are one marker that helps to guide treatment decisions in patients suffering from severe forms of asthma. Effects of type 2 cytokines were analyzed, alone or in combination, on eosinophils in blood and other compartments and on the development of asthma symptoms. C57BL/6 mice received a single intranasal application of equimolar amounts of IL-5, IL-13, and IL-4, alone or in combination. Numbers, activation state, and migratory behavior of eosinophils in bone marrow (BM), blood, lung, and bron…

medicine.medical_treatmentImmunologyMedizinMice03 medical and health sciencesTh2 Cells0302 clinical medicineMetaplasiamedicineAnimalsHumansImmunology and AllergyEosinophiliaLungCells CulturedAsthmaGoblet cellInterleukin-13Lungmedicine.diagnostic_testbusiness.industryrespiratory systemEosinophilmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsMice Inbred C57BLDisease Models AnimalBronchoalveolar lavagemedicine.anatomical_structureCytokineImmunologyAirway RemodelingFemaleInterleukin-4Interleukin-5medicine.symptombusiness030215 immunologyThe Journal of Immunology
researchProduct

Real-world experience with dupilumab in severe asthma: One-year data from an italian named patient program

2021

Raffaele Campisi,1 Claudia Crimi,1 Santi Nolasco,2 Bianca Beghè,3 Leonardo Antonicelli,4 Gabriella Guarnieri,5 Nicola Scichilone,6 Morena Porto,2 Luigi Macchia,7 Giulia Scioscia,8 Maria Pia Foschino Barbaro,8 Alberto Papi,9 Nunzio Crimi1,2 1Respiratory Medicine Unit, A.O.U. Policlinico “G. Rodolico -San Marco”, Catania, Italy; 2Department of Clinical and Experimental Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy; 3Respiratory Medicine Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4Allergy Unit, Department of Internal Medicine, Ancona University Hospital, Ancona, Italy; 5Department of Car…

severe asthmaPulmonary and Respiratory MedicineSevere asthmareal-worldmedicine.medical_specialtyTreatment responseSevere asthmaSocio-culturaleDupilumab Named Patient Program Oral corticosteroids Real-world Severe asthmaHypereosinophiliaDupilumaboral corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionNamed Patient Program dupilumab oral corticosteroids real-world severe asthma03 medical and health sciences0302 clinical medicineRandomized controlled triallawdupilumabInternal medicineOral corticosteroidsJournal of Asthma and AllergymedicineImmunology and Allergy0601 history and archaeologyOriginal Research060102 archaeologybusiness.industryRetrospective cohort study06 humanities and the artsRC581-607Named Patient ProgramEosinophilDupilumabmedicine.anatomical_structureReal-world030228 respiratory systemCohortImmunologic diseases. Allergymedicine.symptombusinessDupilumab; Named Patient Program; Oral corticosteroids; Real-world; Severe asthma
researchProduct

Tumor-associated tissue eosinophilia in tongue squamous cell carcinoma

2020

squamous cell carcinomatongueeosinophilia
researchProduct